Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Year-over-year operating cash flow growth rate
Percentile
P36
Within normal range
vs 2Y Ago
-0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -17.30% |
| Q2 2025 | 28.81% |
| Q1 2025 | -31.70% |
| Q4 2024 | 51.97% |
| Q3 2024 | -50.21% |
| Q2 2024 | -8.11% |
| Q1 2024 | 1.55% |
| Q4 2023 | 32.67% |
| Q3 2023 | 18.46% |
| Q2 2023 | 9.51% |
| Q1 2023 | -93.84% |
| Q4 2022 | -36.10% |
| Q3 2022 | -120.47% |
| Q2 2022 | 582.93% |
| Q1 2022 | -14.43% |
| Q4 2021 | 9.59% |
| Q3 2021 | -21.90% |
| Q2 2021 | 18.75% |
| Q1 2021 | 9.84% |
| Q4 2020 | -25.31% |
| Q3 2020 | -10.71% |
| Q2 2020 | 22.94% |
| Q1 2020 | -16.84% |
| Q4 2019 | 10.50% |
| Q3 2019 | -4.39% |
| Q2 2019 | 2.31% |
| Q1 2019 | -28.06% |
| Q4 2018 | 35.18% |
| Q3 2018 | -57.07% |
| Q2 2018 | 22.87% |
| Q1 2018 | -72.30% |
| Q4 2017 | 46.02% |
| Q3 2017 | 17.79% |
| Q2 2017 | -32.84% |
| Q1 2017 | -26.74% |
| Q4 2016 | 23.86% |
| Q3 2016 | 10.47% |
| Q2 2016 | -30.81% |
| Q1 2016 | -19.98% |
| Q4 2015 | -13.29% |